눈염증 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Ocular Inflammation Treatment Market - Scope of Report

TMR's report on the global ocular inflammation treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global ocular inflammation treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ocular inflammation treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the ocular inflammation treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ocular inflammation treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global ocular inflammation treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ocular inflammation treatment market.

The report delves into the competitive landscape of the global ocular inflammation treatment market. Key players operating in the global ocular inflammation treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global ocular inflammation treatment market profiled in this report.

Key Questions Answered in Global ocular inflammation treatment Market Report:

• What is the sales/revenue generated by ocular inflammation treatment across all regions during the forecast period?
• What are the opportunities in the global ocular inflammation treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Ocular Inflammation Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global ocular inflammation treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global ocular inflammation treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global ocular inflammation treatment market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ocular Inflammation Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Ocular Inflammation Treatment Market Analysis and Forecast, 2017 - 2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Treatment Type

• 6.1. Introduction and Definitions
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Treatment Type, 2017 - 2031
  • 6.3.1. Corticosteroids
  • 6.3.2. Antibiotics
  • 6.3.3. Monoclonal Antibodies
  • 6.3.4. Immunosppressant
  • 6.3.5. Cycloplegic Agents
  • 6.3.6. Antivirals
  • 6.3.7. Antifungal
  • 6.3.8. Analgesics
• 6.4. Market Attractiveness, by Treatment Type

7. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Disease Type

• 7.1. Introduction and Definitions
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Disease Type, 2017 - 2031
  • 7.3.1. Anterior Uveitis
  • 7.3.2. Posterior Uveitis
  • 7.3.3. Pan Uveitis
  • 7.3.4. Intermediate Uveitis
  • 7.3.5. Episcleritis/Scleritis
  • 7.3.6. 7.4 Market Attractiveness, by Disease Type

8. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Mode of Administration

• 8.1. Introduction and Definitions
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Mode of Administration, 2017 - 2031
  • 8.3.1. Topical
  • 8.3.2. Injectable
  • 8.3.3. Oral
  • 8.3.4. Others
• 8.4. Market Attractiveness, by Mode of Administration

9. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Distribution Channel

• 9.1. Introduction and Definitions
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
  • 9.3.4. Drug Stores
• 9.4. Market Attractiveness, by Distribution Channel

10. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region, 2017 - 2031
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness, by Region

11. North America Ocular Inflammation Treatment Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Treatment Type, 2017 - 2031
  • 11.2.1. Corticosteroids
  • 11.2.2. Antibiotics
  • 11.2.3. Monoclonal Antibodies
  • 11.2.4. Immunosppressant
  • 11.2.5. Cycloplegic Agents
  • 11.2.6. Antivirals
  • 11.2.7. Antifungal
  • 11.2.8. Analgesics
• 11.3. Market Attractiveness, by Treatment Type
• 11.4. Market Value Forecast, by Disease Type, 2017 - 2031
  • 11.4.1. Anterior Uveitis
  • 11.4.2. Posterior Uveitis
  • 11.4.3. Pan Uveitis
  • 11.4.4. Intermediate Uveitis
  • 11.4.5. Episcleritis/Scleritis
• 11.5. Market Attractiveness, by Disease Type
• 11.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
  • 11.6.1. Topical
  • 11.6.2. Injectable
  • 11.6.3. Oral
  • 11.6.4. Others
• 11.7. Market Attractiveness, by Mode of Administration
• 11.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
  • 11.8.1. Hospital Pharmacies
  • 11.8.2. Retail Pharmacies
  • 11.8.3. Online Pharmacies
  • 11.8.4. Drug Stores
• 11.9. Market Attractiveness, by Distribution Channel
• 11.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 11.10.1. U.S.
  • 11.10.2. Canada
• 11.11. Market Attractiveness Analysis
  • 11.11.1. By Treatment Type
  • 11.11.2. By Disease Type
  • 11.11.3. By Mode of Administration
  • 11.11.4. By Distribution Channel
  • 11.11.5. By Country

12. Europe Ocular Inflammation Treatment Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Treatment Type, 2017 - 2031
  • 12.2.1. Corticosteroids
  • 12.2.2. Antibiotics
  • 12.2.3. Monoclonal Antibodies
  • 12.2.4. Immunosppressant
  • 12.2.5. Cycloplegic Agents
  • 12.2.6. Antivirals
  • 12.2.7. Antifungal
  • 12.2.8. Analgesics
• 12.3. Market Attractiveness, by Treatment Type
• 12.4. Market Value Forecast, by Disease Type, 2017 - 2031
  • 12.4.1. Anterior Uveitis
  • 12.4.2. Posterior Uveitis
  • 12.4.3. Pan Uveitis
  • 12.4.4. Intermediate Uveitis
  • 12.4.5. Episcleritis/Scleritis
• 12.5. Market Attractiveness, by Disease Type
• 12.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
  • 12.6.1. Topical
  • 12.6.2. Injectable
  • 12.6.3. Oral
  • 12.6.4. Others
• 12.7. Market Attractiveness, by Mode of Administration
• 12.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
  • 12.8.1. Hospital Pharmacies
  • 12.8.2. Retail Pharmacies
  • 12.8.3. Online Pharmacies
  • 12.8.4. Drug Stores
• 12.9. Market Attractiveness, by Distribution Channel
• 12.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 12.10.1. Germany
  • 12.10.2. U.K.
  • 12.10.3. France
  • 12.10.4. Italy
  • 12.10.5. Spain
  • 12.10.6. Rest of Europe
• 12.11. Market Attractiveness Analysis
  • 12.11.1. By Treatment Type
  • 12.11.2. By Disease Type
  • 12.11.3. By Mode of Administration
  • 12.11.4. By Distribution Channel
  • 12.11.5. By Country/Sub-region

13. Asia Pacific Ocular Inflammation Treatment Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Treatment Type, 2017 - 2031
  • 13.2.1. Corticosteroids
  • 13.2.2. Antibiotics
  • 13.2.3. Monoclonal Antibodies
  • 13.2.4. Immunosppressant
  • 13.2.5. Cycloplegic Agents
  • 13.2.6. Antivirals
  • 13.2.7. Antifungal
  • 13.2.8. Analgesics
• 13.3. Market Attractiveness, by Treatment Type
• 13.4. Market Value Forecast, by Disease Type, 2017 - 2031
  • 13.4.1. Anterior Uveitis
  • 13.4.2. Posterior Uveitis
  • 13.4.3. Pan Uveitis
  • 13.4.4. Intermediate Uveitis
  • 13.4.5. Episcleritis/Scleritis
• 13.5. Market Attractiveness, by Disease Type
• 13.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
  • 13.6.1. Topical
  • 13.6.2. Injectable
  • 13.6.3. Oral
  • 13.6.4. Others
• 13.7. Market Attractiveness, by Mode of Administration
• 13.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
  • 13.8.1. Hospital Pharmacies
  • 13.8.2. Retail Pharmacies
  • 13.8.3. Online Pharmacies
  • 13.8.4. Drug Stores
• 13.9. Market Attractiveness, by Distribution Channel
• 13.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 13.10.1. China
  • 13.10.2. Japan
  • 13.10.3. India
  • 13.10.4. Australia & New Zealand
  • 13.10.5. Rest of Asia Pacific
• 13.11. Market Attractiveness Analysis
  • 13.11.1. By Treatment Type
  • 13.11.2. By Disease Type
  • 13.11.3. By Mode of Administration
  • 13.11.4. By Distribution Channel
  • 13.11.5. By Country/Sub-region

14. Latin America Ocular Inflammation Treatment Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Treatment Type, 2017 - 2031
  • 14.2.1. Corticosteroids
  • 14.2.2. Antibiotics
  • 14.2.3. Monoclonal Antibodies
  • 14.2.4. Immunosppressant
  • 14.2.5. Cycloplegic Agents
  • 14.2.6. Antivirals
  • 14.2.7. Antifungal
  • 14.2.8. Analgesics
• 14.3. Market Attractiveness, by Treatment Type
• 14.4. Market Value Forecast, by Disease Type, 2017 - 2031
  • 14.4.1. Anterior Uveitis
  • 14.4.2. Posterior Uveitis
  • 14.4.3. Pan Uveitis
  • 14.4.4. Intermediate Uveitis
  • 14.4.5. Episcleritis/Scleritis
• 14.5. Market Attractiveness, by Disease Type
• 14.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
  • 14.6.1. Topical
  • 14.6.2. Injectable
  • 14.6.3. Oral
  • 14.6.4. Others
• 14.7. Market Attractiveness, by Mode of Administration
• 14.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
  • 14.8.1. Hospital Pharmacies
  • 14.8.2. Retail Pharmacies
  • 14.8.3. Online Pharmacies
  • 14.8.4. Drug Stores
• 14.9. Market Attractiveness, by Distribution Channel
• 14.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 14.10.1. Brazil
  • 14.10.2. Mexico
  • 14.10.3. Rest of Latin America
• 14.11. Market Attractiveness Analysis
  • 14.11.1. By Treatment Type
  • 14.11.2. By Disease Type
  • 14.11.3. By Mode of Administration
  • 14.11.4. By Distribution Channel
  • 14.11.5. By Country/Sub-region

15. Middle East & Africa Ocular Inflammation Treatment Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Treatment Type, 2017 - 2031
  • 15.2.1. Corticosteroids
  • 15.2.2. Antibiotics
  • 15.2.3. Monoclonal Antibodies
  • 15.2.4. Immunosppressant
  • 15.2.5. Cycloplegic Agents
  • 15.2.6. Antivirals
  • 15.2.7. Antifungal
  • 15.2.8. Analgesics
• 15.3. Market Attractiveness, by Treatment Type
• 15.4. Market Value Forecast, by Disease Type, 2017 - 2031
  • 15.4.1. Anterior Uveitis
  • 15.4.2. Posterior Uveitis
  • 15.4.3. Pan Uveitis
  • 15.4.4. Intermediate Uveitis
  • 15.4.5. Episcleritis/Scleritis
• 15.5. Market Attractiveness, by Disease Type
• 15.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
  • 15.6.1. Topical
  • 15.6.2. Injectable
  • 15.6.3. Oral
  • 15.6.4. Others
• 15.7. Market Attractiveness, by Mode of Administration
• 15.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
  • 15.8.1. Hospital Pharmacies
  • 15.8.2. Retail Pharmacies
  • 15.8.3. Online Pharmacies
  • 15.8.4. Drug Stores
• 15.9. Market Attractiveness, by Distribution Channel
• 15.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 15.10.1. GCC Countries
  • 15.10.2. South Africa
  • 15.10.3. Rest of Middle East & Africa
• 15.11. Market Attractiveness Analysis
  • 15.11.1. By Treatment Type
  • 15.11.2. By Disease Type
  • 15.11.3. By Mode of Administration
  • 15.11.4. By Distribution Channel
  • 15.11.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 16.2. Market Share Analysis, by Company (2022)
• 16.3. Company Profiles
  • 16.3.1. Bausch Health Companies, Inc.
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Product Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. SWOT Analysis
    • 16.3.1.5. Strategic Overview
  • 16.3.2. Pfizer Inc.
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Product Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. SWOT Analysis
    • 16.3.2.5. Strategic Overview
  • 16.3.3. Novartis AG
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Product Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. SWOT Analysis
    • 16.3.3.5. Strategic Overview
  • 16.3.4. AbbVie, Inc.
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Product Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. SWOT Analysis
    • 16.3.4.5. Strategic Overview
  • 16.3.5. Cipla Inc.
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Product Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. SWOT Analysis
    • 16.3.5.5. Strategic Overview
  • 16.3.6. AKRON, Inc.
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Product Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. SWOT Analysis
    • 16.3.6.5. Strategic Overview
  • 16.3.7. EyeGate
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Product Portfolio
    • 16.3.7.3. Financial Overview
    • 16.3.7.4. SWOT Analysis
    • 16.3.7.5. Strategic Overview
  • 16.3.8. Alimera Sciences
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Product Portfolio
    • 16.3.8.3. Financial Overview
    • 16.3.8.4. SWOT Analysis
    • 16.3.8.5. Strategic Overview
  • 16.3.9. EyePoint Pharmaceuticals, Inc.
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Product Portfolio
    • 16.3.9.3. Financial Overview
    • 16.3.9.4. SWOT Analysis
    • 16.3.9.5. Strategic Overview